The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the FDA with priority review.

Barcelona-based Sycai Medical has closed a €3M funding round backed by LUMO Labs, Ship2B Ventures, Athos Capital, and Namarel Ventures.

Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S. president, becoming the second to serve two non-consecutive terms.

Researchers in Spain are working to develop faster, more accurate methods for detecting viruses like human norovirus and hepatitis A in fresh produce. The

Caffeine isn’t the only good thing about drinking coffee on the regular. "Coffee is also a unique source of soluble fiber ," Giulio Quarta, MD, a gastroenterologist at Gastroenterology Associates of New Jersey, tells Well+Good.

Edgecore Networks, a global leader in open infrastructure solutions, is thrilled to showcase its powerful Open Infrastructure solutions for AI, Telecom access and aggregation and the large enterprise at Mobile World Congress (MWC) 2025 in

Broadvoice, a leading global customer experience technology provider, announced today the launch of its 2025 CX World Tour, designed to introduce partners, distributors and end-users to its new Global Partner Program and award-winning

Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), according to results from the CARES-005 study.

Our Bureau, Bengaluru Monday, January 20, 2025, 14:30 Hrs [IST]

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood cancer patients.

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, reaching US$2.45 billion in 2024 and an impressive US$11.52 billion by 2030. The growth is attributed to the increasing healthcare expenditures,

Bioinformatics allowed me to address these questions faster and with a broader perspective. The growing availability of public data facilitated this. However, the transition wasn’t easy. I tried many online courses,